Security
TLSA · Tiziana Life Sciences Ltd
TLSANASDAQCommon stockCurrentCIK 1723069Updated Sep 26, 2026
Name history
Tiziana Life Sciences plc · through Oct 21, 2021
TLSA price & chart
Loading TradingView…
NASDAQ:TLSA on TradingView ↗In the news
No coverage from other publishers is available.
Recent filings
Show 5 more recent filings
Financials
FY 2024 · USDSource
Source
cash flow · annual statements
| Line item | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|
| Cash flows from operating activities: | ||||
| Profit or LossUSD | -11,863,000Source | -17,691,000Source | -15,397,000Source | -23,417,000Source |
| Additional Financial Items | ||||
| AdjustmentsForSharebasedPaymentsUSD | 910,000Source | — | — | — |
| IncomeTaxesPaidRefundClassifiedAsOperatingActivitiesUSD | — | — | -490,000Source | -1,415,000Source |
income statement · annual statements
| Line item | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|
| Additional Financial Items | ||||
| BasicEarningsLossPerShareUSD per share | -0.11Source | -0.17Source | -0.15Source | — |
| CurrentTaxExpenseIncomeUSD | -4,883,000Source | 449,000Source | — | -3,255,000Source |
| DepreciationRightofuseAssetsUSD | 112,000Source | 89,000Source | 50,000Source | 133,000Source |
| DilutedEarningsLossPerShareUSD per share | -0.11Source | -0.17Source | -0.15Source | — |
| EmployeeBenefitsExpenseUSD | 5,587,000Source | 4,596,000Source | 1,242,000Source | 9,973,000Source |
| ExpenseFromSharebasedPaymentTransactionsWithEmployeesUSD | 2,338,000Source | 1,730,000Source | -1,410,000Source | 5,173,000Source |
| FinanceCostsUSD | 1,766,000Source | — | — | — |
| FinanceIncomeUSD | 814,000Source | 1,154,000Source | — | — |
| IncomeTaxExpenseContinuingOperationsUSD | -4,883,000Source | 449,000Source | — | -3,313,000Source |
| InterestExpenseOnLeaseLiabilitiesUSD | 6,000Source | 10,000Source | 7,000Source | 13,000Source |
| OtherIncomeUSD | — | — | — | 893,000Source |
| OtherOperatingIncomeExpenseUSD | — | — | -1,631,000Source | -13,311,000Source |
| PostemploymentBenefitExpenseDefinedContributionPlansUSD | 21,000Source | 56,000Source | 32Source | 24,000Source |
| ProfitLossBeforeTaxUSD | -16,746,000Source | -17,242,000Source | -15,397,000Source | -26,657,000Source |
| ProfitLossFromOperatingActivitiesUSD | -15,794,000Source | -17,984,000Source | -14,586,000Source | -27,374,000Source |
| ResearchAndDevelopmentExpenseUSD | 5,229,000Source | 8,113,000Source | 12,955,000Source | 13,208,000Source |
| RevenueFromInterestUSD | 1,150,000Source | — | — | — |
Filing attachments
ea030608701ex99-1.htm · 6-K · 2026-09-21
EX-99.1 2 ea030608701ex99-1.htm TIZIANA LIFE SCIENCES LTD PRESS RELEASE, DATED SEPTEMBER 21, 2026 Exhibit 99.1 Tiziana Announces Last Patient Completes Last Visit in Phase 2a INFORM-MS Trial of Intranasal Foralumab BOSTON, MA, September 21, 2026 - Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal foralumab, a fully human, anti-CD3 monoclonal anti…
Read attachment ↗